Get the Stockscreener App
72.37
0.00%
0.00
After Hours:
72.37
Avidity Biosciences Inc stock is traded at $72.37, with a volume of 1.11M.
It is up +0.00% in the last 24 hours and up +1.50% over the past month.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$72.37
Open:
$72.33
24h Volume:
1.11M
Relative Volume:
0.24
Market Cap:
$10.90B
Revenue:
$10.73M
Net Income/Loss:
$-455.74M
P/E Ratio:
-20.35
EPS:
-3.5569
Net Cash Flow:
$-502.70M
1W Performance:
+0.37%
1M Performance:
+1.50%
6M Performance:
+131.44%
1Y Performance:
+141.80%
1-Day Range:
$72.30
$72.41
1-Week Range:
$72.00
$72.47
52-Week Range:
$21.51
$72.61
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
72.37 | 10.90B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Roth Capital | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Bernstein | Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Jun-11-25 | Initiated | Raymond James | Strong Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Why Avidity Biosciences Inc. stock attracts high net worth investors2025 Historical Comparison & Free Fast Entry Momentum Trade Alerts - ulpravda.ru
Will Avidity Biosciences Inc. stock gain from strong economyOil Prices & Free Verified High Yield Trade Plans - ulpravda.ru
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James - MSN
The Technical Signals Behind (RNA) That Institutions Follow - Stock Traders Daily
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Is Avidity Biosciences Inc a good long term investmentStock Price Divergence & Market Monitoring and Alerts - earlytimes.in
Avidity Biosciences Earnings Notes - Trefis
Is Avidity Biosciences Inc. stock resilient to inflationSupport Zone Identification & High Return Trading Ideas - bollywoodhelpline.com
CEO Moves: Is Avidity Biosciences Inc stock a buy on dipsSwing Trade & Weekly High Return Opportunities - moha.gov.vn
Novartis to acquire Avidity Biosciences for about $12 billion - MSN
Assenagon Asset Management S.A. Has $2 Million Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
How Avidity Biosciences Inc. stock valuations compare to rivalsQuarterly Market Summary & Risk Adjusted Buy/Sell Alerts - Улправда
Exit Recap: Is Avidity Biosciences Inc. stock resilient to inflationJuly 2025 Spike Watch & Long-Term Growth Plans - ulpravda.ru
Avidity Biosciences stock hits all-time high at 72.23 USD By Investing.com - Investing.com South Africa
Avidity Biosciences stock hits all-time high at 72.23 USD - Investing.com
Officer Calderaro III Surrenders 9,726 Of Avidity Biosciences Inc [RNA] - TradingView — Track All Markets
Officer Flanagan Surrenders 13,695 Of Avidity Biosciences Inc [RNA] - TradingView — Track All Markets
Officer Mosbrooker Surrenders 47,990 Of Avidity Biosciences Inc [RNA] - TradingView — Track All Markets
Officer Gallagher Surrenders 41,366 Of Avidity Biosciences Inc [RNA] - TradingView — Track All Markets
Officer McCarthy Acquires 21,702 Of Avidity Biosciences Inc [RNA] - TradingView — Track All Markets
Avidity Biosciences (NASDAQ:RNA) Lowered to Hold Rating by Evercore ISI - MarketBeat
RNA SEC FilingsAvidity Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Avidity Biosciences receives FTC clearance for Novartis merger - MSN
Avidity reports FTC granted request for early termination of HSR waiting period - MSN
Novartis-Avidity Biosciences deal gets early clearance in US - MLex
Evercore ISI Downgrades Avidity Biosciences to In Line From Outperform, Adjusts Price Target to $72 From $65 - marketscreener.com
Avidity Biosciences Receives FTC Clearance for Novartis Merger - TipRanks
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week HighHere's Why - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Mirador Capital Partners LP Purchases 22,666 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Top 2 Health Care Stocks That May Keep You Up At Night In December - Benzinga
Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity - MSN
Frazier Life Sciences Management L.P. Has $17.75 Million Stock Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Reaches New 52-Week HighWhat's Next? - MarketBeat
EcoR1 Capital LLC Sells 57,576 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences stock hits all-time high at 71.81 USD By Investing.com - Investing.com Australia
Avidity Biosciences stock hits all-time high at 71.81 USD - Investing.com
Aug Closing: Is Avidity Biosciences Inc stock vulnerable to regulatory risksTrade Performance Summary & Growth-Oriented Investment Plans - moha.gov.vn
Avoiding Lag: Real-Time Signals in (RNA) Movement - news.stocktradersdaily.com
Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger - MSN
Assessing Avidity Biosciences (RNA) Valuation After a 130% Year-to-Date Share Price Surge - Yahoo Finance
Dyne stock upgraded at Oppenheimer (DYN:NASDAQ) - Seeking Alpha
Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says - marketscreener.com
Norges Bank Makes New Investment in Avidity Biosciences, Inc. $RNA - MarketBeat
Franklin Resources Inc. Sells 29,465 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
JPMorgan Chase & Co. Buys 139,473 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences stock hits all-time high at 71.78 USD By Investing.com - Investing.com South Africa
Avidity Biosciences stock hits all-time high at 71.78 USD - Investing.com
Why Avidity Biosciences Inc. stock could benefit from AI revolution2025 Breakouts & Breakdowns & Free Expert Approved Momentum Trade Ideas - Newser
Avidity Biosciences, Inc. (RNA): A Bull Case Theory - Finviz
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):